AGIOS PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34.54 USD | -0.12% |
|
+9.69% | +55.10% |
| May. 02 | Agios Pharmaceuticals Shares Rise After Reporting Smaller Q1 Loss | MT |
| May. 02 | Transcript : Agios Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024 |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,265 | 3,001 | 1,785 | 1,543 | 1,245 | 1,961 | - | - |
| Enterprise Value (EV) 1 | 3,184 | 2,690 | 1,582 | 1,421 | 1,215 | 1,884 | 1,946 | 1,735 |
| P/E ratio | -6.96 x | -9.14 x | 1.24 x | -6.64 x | -3.52 x | -6.43 x | -6.09 x | -7.43 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 27.7 x | 14.8 x | - | 108 x | 46.4 x | 46.1 x | 16.9 x | 9.42 x |
| EV / Revenue | 27 x | 13.2 x | - | 99.8 x | 45.3 x | 44.2 x | 16.7 x | 8.33 x |
| EV / EBITDA | -7.61 x | -8.79 x | -4.29 x | -3.73 x | -3.16 x | -4.65 x | -4.93 x | -5.43 x |
| EV / FCF | -8.32 x | -8.8 x | -3.83 x | -4.52 x | -4.09 x | -5.89 x | -8.2 x | -7.73 x |
| FCF Yield | -12% | -11.4% | -26.1% | -22.1% | -24.5% | -17% | -12.2% | -12.9% |
| Price to Book | 4.47 x | 7.48 x | 1.54 x | 1.4 x | 1.53 x | 2.77 x | 3.02 x | 3.73 x |
| Nbr of stocks (in thousands) | 68,371 | 69,260 | 54,308 | 54,945 | 55,891 | 56,773 | - | - |
| Reference price 2 | 47.75 | 43.33 | 32.87 | 28.08 | 22.27 | 34.54 | 34.54 | 34.54 |
| Announcement Date | 2/13/20 | 2/25/21 | 2/24/22 | 2/23/23 | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 117.9 | 203.2 | - | 14.24 | 26.82 | 42.58 | 116.4 | 208.2 |
| EBITDA 1 | -418.2 | -306.2 | -369.2 | -380.5 | -384.9 | -405 | -394.6 | -319.6 |
| EBIT 1 | -426.3 | -316.1 | -378.4 | -389 | -391.5 | -392.4 | -362.8 | -302.6 |
| Operating Margin | -361.57% | -155.59% | - | -2,732.07% | -1,459.52% | -921.64% | -311.78% | -145.38% |
| Earnings before Tax (EBT) 1 | -411.5 | -327.4 | -356.5 | -231.8 | -352.1 | -249.4 | -317.8 | -281.6 |
| Net income 1 | -411.5 | -327.4 | 1,605 | -231.8 | -352.1 | -270.2 | -350.8 | -315.5 |
| Net margin | -348.97% | -161.11% | - | -1,627.82% | -1,312.63% | -634.59% | -301.47% | -151.59% |
| EPS 2 | -6.860 | -4.740 | 26.55 | -4.230 | -6.330 | -5.369 | -5.674 | -4.652 |
| Free Cash Flow 1 | -382.8 | -305.7 | -413.1 | -314.4 | -297.1 | -319.9 | -237.2 | -224.4 |
| FCF margin | -324.64% | -150.43% | - | -2,207.58% | -1,107.49% | -751.28% | -203.83% | -107.79% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/13/20 | 2/25/21 | 2/24/22 | 2/23/23 | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 0.832 | 5.582 | 3.516 | 4.31 | 5.609 | 6.712 | 7.399 | 7.103 | 8.189 | 9.607 | 11.21 | 12.94 | 26.84 |
| EBITDA 1 | -88.94 | - | - | - | - | - | -88.82 | -91.89 | - | -104.9 | -100 | -99 | -100 | 100 | - |
| EBIT 1 | -91.15 | -104.8 | -101.1 | -97.64 | -91.09 | -99.17 | -90.61 | -93.7 | -100.9 | -106.3 | -92.07 | -98.1 | -98.74 | -77.35 | -92.87 |
| Operating Margin | - | - | -12,156.85% | -1,749.19% | -2,590.73% | -2,300.97% | -1,615.49% | -1,396.01% | -1,363.66% | -1,496.23% | -1,124.34% | -1,021.13% | -880.82% | -597.65% | -346% |
| Earnings before Tax (EBT) 1 | -84.26 | -98.58 | -94.77 | -91.81 | -81.75 | 36.53 | -81.02 | -83.81 | -91.32 | -95.94 | -81.55 | -90.19 | -86.16 | 107.9 | -77.55 |
| Net income 1 | -88.77 | -94.63 | -94.77 | -91.81 | -81.75 | 36.53 | -81.02 | -83.81 | -91.32 | -95.94 | -81.55 | -90.19 | -90.49 | 107.9 | -77.55 |
| Net margin | - | - | -11,391.11% | -1,644.68% | -2,325% | 847.47% | -1,444.43% | -1,248.6% | -1,234.27% | -1,350.7% | -995.84% | -938.72% | -807.24% | 833.66% | -288.92% |
| EPS 2 | -1.560 | -1.740 | -1.740 | -1.680 | -1.490 | 0.6700 | -1.470 | -1.510 | -1.640 | -1.720 | -1.450 | -1.590 | -1.591 | 0.6776 | -1.530 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/3/21 | 2/24/22 | 5/5/22 | 8/4/22 | 11/3/22 | 2/23/23 | 5/4/23 | 8/3/23 | 11/2/23 | 2/15/24 | 5/2/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 80.9 | 311 | 203 | 122 | 30.1 | 76.8 | 15.4 | 226 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -383 | -306 | -413 | -314 | -297 | -320 | -237 | -224 |
| ROE (net income / shareholders' equity) | -62% | -63% | 190% | -19.4% | -36.8% | -42.5% | -43.4% | -26.5% |
| ROA (Net income/ Total Assets) | -47% | -37.5% | 140% | -17.3% | -32.4% | -17.9% | -36.7% | -22.4% |
| Assets 1 | 874.6 | 871.8 | 1,145 | 1,338 | 1,088 | 1,510 | 955.4 | 1,410 |
| Book Value Per Share 2 | 10.70 | 5.790 | 21.40 | 20.10 | 14.60 | 12.50 | 11.40 | 9.250 |
| Cash Flow per Share 2 | - | - | -6.740 | -5.650 | -5.320 | -4.770 | -4.640 | - |
| Capex 1 | 12.2 | 14.9 | 5.74 | 4.88 | 1 | 5.5 | 8 | 20 |
| Capex / Sales | 10.32% | 7.34% | - | 34.28% | 3.72% | 12.92% | 6.87% | 9.61% |
| Announcement Date | 2/13/20 | 2/25/21 | 2/24/22 | 2/23/23 | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
34.54
USD
Average target price
41.67
USD
Spread / Average Target
+20.63%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +55.10% | 1.96B | |
| -1.43% | 104B | |
| +8.96% | 105B | |
| +4.40% | 22.94B | |
| -12.15% | 22.34B | |
| -4.36% | 19.25B | |
| -39.98% | 17.08B | |
| -10.04% | 16.96B | |
| +6.79% | 14.16B | |
| +38.61% | 12.63B |
- Stock Market
- Equities
- AGIO Stock
- Financials Agios Pharmaceuticals, Inc.
